What is Zacks Small Cap’s Estimate for ABEO Q1 Earnings?

Abeona Therapeutics Inc (NASDAQ:ABEO) – Zacks Small Cap issued their Q1 2025 earnings per share (EPS) estimates for Abeona Therapeutics in a research note issued to investors on Monday, March 24th. Zacks Small Cap analyst D. Bautz forecasts that the biopharmaceutical company will post earnings of ($0.34) per share for the quarter. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics’ Q2 2025 earnings at ($0.33) EPS.

Several other analysts also recently commented on the company. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Monday. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Finally, Oppenheimer assumed coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price objective for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Trading Up 1.0 %

ABEO opened at $5.04 on Wednesday. The company has a fifty day moving average price of $5.42 and a two-hundred day moving average price of $5.81. Abeona Therapeutics has a 1-year low of $3.05 and a 1-year high of $8.45. The company has a market cap of $219.09 million, a P/E ratio of -1.87 and a beta of 1.79. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19.

Institutional Trading of Abeona Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Adage Capital Partners GP L.L.C. grew its holdings in Abeona Therapeutics by 20.1% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock worth $21,736,000 after buying an additional 652,366 shares in the last quarter. Western Standard LLC grew its stake in shares of Abeona Therapeutics by 22.8% in the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock worth $11,610,000 after acquiring an additional 386,321 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Abeona Therapeutics by 894.8% in the fourth quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company’s stock valued at $732,000 after purchasing an additional 118,262 shares during the last quarter. 683 Capital Management LLC lifted its position in shares of Abeona Therapeutics by 17.3% during the fourth quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock valued at $4,411,000 after purchasing an additional 116,845 shares in the last quarter. Finally, Wellington Management Group LLP purchased a new position in Abeona Therapeutics during the fourth quarter worth about $520,000. 80.56% of the stock is owned by hedge funds and other institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.